Adaptimmune Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May '26 May 7, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	0	138	180	239	586	834
Market Cap Growth	-99.42%	-23.47%	-24.70%	-59.17%	-29.79%	561.07%
Enterprise Value	23	26	44	62	372	458
Last Close Price	0.00	0.54	0.79	1.46	3.75	5.39
PS Ratio	0.01	0.77	2.99	8.81	95.26	210.78
PB Ratio	-0.01	11.63	4.56	2.92	2.84	2.44
P/TBV Ratio	-	17.30	4.60	2.94	2.86	2.46
P/FCF Ratio	-	-	-	-	271.82	-
P/OCF Ratio	-	-	-	-	54.60	-
EV/Sales Ratio	0.35	0.15	0.73	2.28	60.44	115.73
EV/FCF Ratio	-0.12	-	-	-	172.44	-
Debt / Equity Ratio	-0.69	6.26	0.64	0.28	0.12	0.07
Debt / FCF Ratio	-	-	-	-	11.82	-
Net Debt / Equity Ratio	-0.32	-6.53	-3.08	-2.22	-1.67	-1.01
Net Debt / EBITDA Ratio	-0.16	1.88	1.01	1.15	2.21	2.74
Net Debt / FCF Ratio	-0.12	1.05	0.84	1.06	-159.68	6.16
Asset Turnover	0.29	0.67	0.20	0.07	0.01	0.01
Inventory Turnover	20.28	34.25	97.02	126.15	78.45	51.66
Quick Ratio	1.07	2.60	2.66	3.76	6.45	9.96
Current Ratio	1.52	2.92	2.85	3.96	6.64	10.19
Return on Equity (ROE)	-1341.10%	-275.75%	-187.61%	-114.97%	-57.78%	-55.97%
Return on Assets (ROA)	-40.86%	-12.39%	-26.71%	-25.67%	-22.03%	-26.36%
Return on Capital Employed (ROCE)	-186.90%	-28.90%	-62.30%	-62.00%	-39.90%	-32.40%
Earnings Yield	-42697.64%	-51.37%	-63.22%	-69.17%	-26.99%	-15.59%
FCF Yield	-48208.77%	-53.75%	-80.82%	-71.60%	0.37%	-6.70%
Buyback Yield / Dilution	-8.53%	-25.48%	-24.73%	-3.47%	-9.37%	-35.72%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.